



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Brimonidine gel (Mirvaso®)
Indication under review	Symptomatic treatment of facial erythema of rosacea in adult patients
Policy No:	APC 090
Date of Issue:	November 2014
Review Date:	November 2017
Policy Statement: Brimonidine gel (Mirvaso®) is an option for the treatment of a cohort of patients with rosacea characterised by symptomatic facial erythema and flushing not responding to standard treatment or life style measures.	
Traffic Light Status	Green
Key Points considered:	
<ul style="list-style-type: none"> • In a 1-year study assessing the long-term safety and efficacy of treatment with brimonidine effect of topical brimonidine gel on erythema severity was observed after the first application and the durability of the effect was maintained until the end of the study at month 12, with no tachyphylaxis observed. • A comparative crossover study conducted to assess the efficacy of brimonidine gel (BG) vs azelaic acid gel (AG) showed that the percentage of subjects with a 2-grade improvement for clinician's erythema assessment was 37.1% and 11.4% for BG and AG, respectively and those with a 2-grade improvement in patient self-assessment was 28.6% and 20.0% for BG and AG, respectively 	
References:	
<ol style="list-style-type: none"> 1. SPC Mirvaso accessible via http://www.medicines.org.uk/emc/medicine/28682/SPC/Mirvaso+3mg+g+Gel/ 2. Rosacea. Patient.Co http://www.patient.co.uk/health/Rosacea.htm 3. Ilkovitch D, Pomerantz RG. Journal of the American Academy of Dermatology, 05 2014, vol./is. 70/5(e109-10), 0190-9622;1097-6787 (2014 May) 4. Joseph Fowler Jr. MD,^a J. Mark Jackson MD,^a Angela Moore MD,^b Michael Jarratt MD,^c Terry Jones MD,^d Kappa Meadows MD,^e Martin Steinhoff MD,^f Diane Rudisill BSc,^g and Matthew Leoni MD^g on behalf of the Brimonidine Phase III Study Group. Efficacy and Safety of Once-Daily Topical Brimonidine Tartrate Gel 0.5% for the Treatment of Moderate to Severe Facial Erythema of Rosacea: Results of Two Randomized, Double-blind, and Vehicle-Controlled Pivotal Studies. Vol 12, issue 6, Journal of Drugs in Dermatology. 5. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M, Moore A, Kempers S, Murakawa G., Weiss J., Tauscher A., Swinyer L., Liu H., Leoni M Kendall J., Winkelman W, Value in Health, May 2014, vol./is. 17/3(A181-A182), 1098-3015 (May 2014) Brimonidine Phase II Study Group British Journal of Dermatology, 03 2012, vol./is. 166/3(633-41), 0007-0963;1365-2133 (2012 Mar) 	
Date taken to APC:	5 th November 2014
Date Ratified by MMC on Behalf of the Board:	12 th November 2014